Background: RGC32, also known as C13orf15, is a 137 amino acid protein that localizes to the cytoplasm, as well as to the nucleus and the centrosome. Expressed at high levels in kidney, pancreas and skeletal muscle and at lower levels in brain, heart and placenta, RGC32 functions to modulate the activity of cell cycle-specific kinases, thereby regulating cell cycle progression. Additionally, RGC32 may promote cell cycle arrest at the G2/M phase transition and is thought to inhibit the growth of glioma cells, possibly functioning as a tumor suppressor. Conversely, overexpression of RGC32 may promote cell replication and assist in the pathogenesis of malignancies, suggesting that RGC32 also participates in tumor transformation and progression. RGC32 activity is induced by complement activation and by p53 in response to DNA damage. Multiple isoforms of RGC32 exist as a result of alternative splicing events.
Description: Rabbit polyclonal to RGC32
Immunogen: KLH conjugated synthetic peptide derived from RGC32
Specificity: ·Reacts with Human, Mouse, Pig, Dog and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 14 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
